In recent years, the incidence of ophthalmic diseases has been on a steady rise, with traditional therapeutic approaches facing considerable limitations in terms of drug delivery efficiency, bioavailability, and targeting capability. As a novel class of functional nanomaterials with enzyme-mimetic catalytic activity, nanozymes not only possess the highly efficient catalytic properties of natural enzymes but also integrate the unique advantages of nanomaterials, such as a large specific surface area, excellent biocompatibility, and targeted delivery potential, thereby offering innovative insights for the treatment of ophthalmic diseases. The synergistic integration strategy of nanozymes with drug molecules can optimize drug release kinetics, enhance targeted accumulation in lesion tissues, and reduce nonspecific damage, which has demonstrated remarkable potential in the treatment of various ophthalmic conditions. This review systematically summarizes the classification system of nanozymes, focuses on elaborating the latest research progress of nanozyme-drug combinations in the management of ophthalmic diseases including glaucoma, dry eye, keratitis, diabetic retinopathy, and retinal neovascularization, and thoroughly analyzes the core advantages of such combinations in improving drug bioavailability, enhancing the precision of targeted delivery, and minimizing adverse effects. It is anticipated to provide theoretical references for the development and clinical translation of innovative therapeutic strategies for ophthalmic diseases.

国家自然科学基金(No.22172119); 陕西省自然科学基金(No.2021JQ-739)